VEGFA and neoplasm: In the pre-clinical rodent studies, losartan’s anti-tumor activity was attributed to anti-angiogenic or anti-TGF-β signaling effects; furthermore, there was evidence that losartan decreases the VEGF expression by regulating the angiogenesis process [37,38].